Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Converting Target Discovery and Validation into Drug Discovery and Drug Development – Especially for Childhood Cancers
Dr. Donald Durden 

Dr. Donald Durden, UC San Diego

A renowned physician-scientist, Donald Durden, M.D., PhD., is Vice Chair for Research at UC San Diego’s Department of Pediatrics and Associate Director for Pediatric Oncology at the Moores UCSD Cancer Center. Durden’s most recent accomplishment is the development and initiation of a clinical trial of the first small molecule inhibitor of PI-3 kinase to enter human clinical trials in cancer.

Read full bio

About the Lab 

About the Durden Lab

The main focus of the Durden laboratory is analyzing mouse models for pediatric cancer in order to better understand signaling pathways that contribute to cancer cell growth. As a result, Durden et al hope to identify the most powerful drug targets for pediatric disease intervention.

More about our research >

News and Updates 

Durden & Castellino Discover New Biomarker for Medulloblastoma Tumor Growth

La Jolla, July 14, 2010 – In an investigative study published in May 2010 Issue of PLoS One, Durden  teamed up with Dr. Craig Castellino at Emory University to report a new role for the PI-3 kinase signaling pathway in a pediatric brain tumor.